[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mauro Martins Teixeira\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100658091","phase-2-evaluation-of-ixchiq-vaccine-immunogenicity-100658091",false,"NCT07846293","Evaluation of IXCHIQ® Vaccine Immunogenicity","Evaluation of Immunogenicity and Duration of Immunity of the IXCHIQ® Vaccine Against CHIKV","IMUNO-CHIQ","Inclusion criteria:\n\n* The participant or guardian understands the procedures and requirements, and is willing and able to provide informed consent for full participation in the study;\n* Individuals of both sexes aged 12 to 59 years.\n\nExclusion Criteria:\n\n* Participants under 12 years of age or 60 years of age or older;\n* Those with any contraindication identified in Ministry of Health Technical Note No. 9\u002F2026-CGFAM\u002FDPNI\u002FSVSA\u002FMS (https:\u002F\u002Fwww.gov.br\u002Fsaude\u002Fpt-br\u002Fcentrais-de-conteudo\u002Fpublicacoes\u002Fnotas-tecnicas\u002F2026\u002Fnota-tecnica-no-9-2026-cgfam-dpni-svsa-ms.pdf - Technical Note: Guidelines for monitoring the safety of the Chikungunya vaccine used during the pilot vaccination strategy in Brazil - 2026);\n* Participants unavailable to attend the planned study visits;\n* Participants who do not agree to sign the Informed Consent Form (ICF);\n* Positive β-hCG test on the day of vaccination, for women of reproductive potential;\n* Participants who are pregnant or planning to become pregnant within the 3 months following the vaccine dose;\n* Participants who are breastfeeding;\n* Participants with a known or suspected immune system defect that could influence the immune response to the vaccine, such as congenital or acquired immunodeficiency-including HIV infection, post-organ transplant status, or immunosuppressive therapy within 4 weeks prior to Visit 1. Immunosuppressive therapy is defined as the chronic administration of prednisone (more than 14 days) or an equivalent at a dosage of ≥2 mg\u002Fkg\u002Fday during the 4 weeks prior to study entry. Note: radiotherapy or cytotoxic immunosuppressive drugs\u002Fmonoclonal antibodies within the previous 3 years; topical and inhaled steroids are permitted.\n* Any clinical instability identified by the attending physician that could place the participant at risk.",true,"ALL","12 Years","59 Years",{"count":22,"type":23},75,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this clinical trial is to evaluate the quality and duration of the immune response against chikungunya virus elicited by the IXCHIQ® vaccine in healthy adults and adolescents. The main questions it aims to answer are:\n\nIs the cellular immune response elicited by IXCHIQ® adequate for Chikungunya prevention? Is the IXCHIQ® vaccine safe? How does the immune response elicited by IXCHIQ® behave at the different time points evaluated?\n\nParticipants will:\n\nReceive the IXCHIQ® vaccine; Be evaluated by medical personnel and have a blood sample taken on days 3, 7, 30, 180, and 720 after vaccination; Be contacted by phone 60 days after vaccination.",[29,30],"Healthy Adult","Healthy Adolescents",[32,33,34],"IXCHIQ","Chikungunya","Immunogenicity","NOT_YET_RECRUITING","2026-09-22",{"date":38,"type":39},"2026-09-29","ACTUAL",{"date":41,"type":23},"2026-09-24",{"date":43,"type":23},"2030-07",{"name":45,"class":46},"Mauro Martins Teixeira","OTHER",""]